DTU Logo
About the DTU | News | Staff | Contact/Find us

DTU Research Fellow presents new findings at the 2016 EASD in Munich


Few data are available on the potential benefits that achieving different HbA1c targets might deliver. Dr Samiul Mostafa, a Diabetes Trials Unit academic clinical lecturer, used the UKPDS Outcomes Model to estimate 10-year risks for micro- and macrovascular type 2 diabetes complications when targeting HbA1c levels between 10% and 6%, to quantify the likely incremental benefits. These simulated outcomes could provide patients and clinicians a guide to the potential glucose-lowering benefits possible when targeting progressively lower HbA1c values from a baseline of 10%.

[Read press report]